Antibodies
The present invention relates to antibodies binding to B7H4, including bispecific antibodies binding to B7H4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
1. An antibody comprising a first antigen-binding region which binds to human B7H4, wherein the first antigen-binding region comprises a variable heavy chain (VH) region comprising:
a CDR1 comprising the sequence of SEQ ID NO: 26,
a CDR2 comprising the sequence of SEQ ID NO: 30, and
a CDR3 comprising the sequence of SEQ ID NO: 28
and a variable light chain (VL) region comprising:
a CDR1 comprising the sequence of SEQ ID NO: 34,
a CDR2 comprising the sequence GAS, and
a CDR3 comprising the sequence of SEQ ID NO: 35, and
said antibody further comprising a second antigen-binding region which binds to human CD3.
2. An antibody comprising a first antigen-binding region which binds to human B7H4, wherein the first antigen-binding region comprises a variable heavy chain (VH) region comprising the sequence of SEQ ID NO. 29 and a variable light chain (VL) region comprising the sequence of SEQ ID NO. 33, said antibody further comprising a second antigen-binding region which binds to human CD3.
3. The antibody according to claim 1 , wherein the second antigen-binding region binds to human CD3ε.
4. The antibody according to claim 1 , wherein the second antigen-binding region comprises a variable heavy chain (VH) region comprising:
a CDR1 comprising the sequence of SEQ ID NO: 18,
a CDR2 comprising the sequence of SEQ ID NO: 19, and
a CDR3 comprising the sequence of SEQ ID NO: 20 or SEQ ID NO: 21,
and a variable light chain (VL) region comprising:
a CDR1 comprising the sequence of SEQ ID NO: 23,
a CDR2 comprising the sequence GTN, and
a CDR3 comprising the sequence of SEQ ID NO: 24.
5. The antibody according to claim 4 , wherein the CDR3 of the VH region of the second antigen-binding region comprises the sequence of SEQ ID NO: 21.
6. The antibody according to claim 2 , wherein the second antigen-binding region comprises a heavy chain variable (VH) region comprising the sequence of SEQ ID NO: 16 or 17 and a light chain variable (VL) region comprising the sequence of SEQ ID NO: 22.
7. The antibody according to claim 6 , wherein the second antigen-binding region comprises a VH region comprising the sequence of SEQ ID NO: 17.
8. The antibody according to claim 5 , wherein the antibody is a full-length antibody.
9. The antibody according to claim 7 , wherein the antibody is a full-length antibody.
10. The antibody according to claim 5 , wherein the antibody comprises a human IgG1 heavy chain constant region.
11. The antibody according to claim 7 , wherein the antibody comprises a human IgG1 heavy chain constant region.
12. The antibody according to claim 5 , wherein said antibody comprises a first heavy chain and a second heavy chain, wherein the amino acid in the position corresponding to K409 in a human IgG1 heavy chain is R in said first heavy chain, and the amino acid in the position corresponding to F405 in a human IgG1 heavy chain is L in said second heavy chain, or vice versa, and wherein the amino acid positions are numbered according to Eu numbering.
13. The antibody according to claim 7 , wherein said antibody comprises a first heavy chain and a second heavy chain, wherein the amino acid in the position corresponding to K409 in a human IgG1 heavy chain is R in said first heavy chain, and the amino acid in the position corresponding to F405 in a human IgG1 heavy chain is L in said second heavy chain, or vice versa, and wherein the amino acid positions are numbered according to Eu numbering.
14. The antibody according to claim 5 , wherein the antibody comprises a first heavy chain and a second heavy chain, and wherein in both the first heavy chain and the second heavy chain, the amino acid residues at the positions corresponding to positions L234, L235 and D265 in a human IgG1 heavy chain according to Eu numbering are F, E and A, respectively.
15. The antibody according to claim 7 , wherein the antibody comprises a first heavy chain and a second heavy chain, and wherein in both the first heavy chain and the second heavy chain, the amino acid residues at the positions corresponding to positions L234, L235 and D265 in a human IgG1 heavy chain according to Eu numbering are F, E and A, respectively.
16. The antibody according to claim 5 , wherein said antibody comprises a human kappa (κ) light chain and/or a human lambda (λ) light chain.
17. The antibody according to claim 7 , wherein said antibody comprises a human kappa (κ) light chain and/or a human lambda (λ) light chain.
18. The antibody according to claim 5 , wherein said first antigen binding region which binds to human B7H4 is comprised in a first heavy chain and a first light chain, said first heavy chain comprising said VH region and a human IgG1 heavy chain constant region and said first light chain comprising said VL region and a human kappa light chain constant region; and wherein said second antigen binding region which binds to human CD3 is comprised in a second heavy chain and a second light chain, said second heavy chain comprising said VH region and a human IgG1 heavy chain constant region and said second light chain comprising said VL region and a human lambda light chain constant region.
19. The antibody according to claim 7 , wherein said first antigen binding region which binds to human B7H4 is comprised in a first heavy chain and a first light chain, said first heavy chain comprising said VH region and a human IgG1 heavy chain constant region and said first light chain comprising said VL region and a human kappa light chain constant region; and wherein said second antigen binding region which binds to human CD3 is comprised in a second heavy chain and a second light chain, said second heavy chain comprising said VH region and a human IgG1 heavy chain constant region and said second light chain comprising said VL region and a human lambda light chain constant region.
20. The antibody according to claim 18 , wherein said first IgG1 heavy chain constant region comprises the sequence of SEQ ID NO. 61 and said second IgG1 heavy chain constant region comprises the sequence of SEQ ID NO. 60, and wherein said kappa light chain constant region comprises the sequence of SEQ ID NO. 63 and said lambda light chain constant region comprises the sequence of SEQ ID NO. 64.
21. The antibody according to claim 19 , wherein said first IgG1 heavy chain constant region comprises the sequence of SEQ ID NO. 61 and said second IgG1 heavy chain constant region comprises the sequence of SEQ ID NO. 60, and wherein said kappa light chain constant region comprises the sequence of SEQ ID NO. 63 and said lambda light chain constant region comprises the sequence of SEQ ID NO. 64.
22. The antibody according to claim 20 , wherein at least one of said IgG1 heavy chain constant regions lacks the C-terminal lysine.
23. The antibody according to claim 21 , wherein at least one of said IgG1 heavy chain constant regions lacks the C-terminal lysine.
24. A bispecific antibody comprising a first antigen-binding region which binds to human B7H4, wherein the first antigen-binding region comprises a variable heavy chain (VH) region comprising:
a CDR1 comprising the sequence of SEQ ID NO: 26,
a CDR2 comprising the sequence of SEQ ID NO: 30, and
a CDR3 comprising the sequence of SEQ ID NO: 28
and a variable light chain (VL) region comprising:
a CDR1 comprising the sequence of SEQ ID NO: 34,
a CDR2 comprising the sequence GAS, and
a CDR3 comprising the sequence of SEQ ID NO: 35, and
said bispecific antibody further comprising a second antigen-binding region which binds to human CD3, wherein the second antigen-binding region comprises a VH region comprising:
a CDR1 comprising the sequence of SEQ ID NO: 18,
a CDR2 comprising the sequence of SEQ ID NO: 19, and
a CDR3 comprising the sequence of SEQ ID NO: 21
and a VL region comprising:
a CDR1 comprising the sequence of SEQ ID NO: 23,
a CDR2 comprising the sequence GTN, and
a CDR3 comprising the sequence of SEQ ID NO: 24.
25. A bispecific antibody comprising a first antigen-binding region which binds to human B7H4, wherein the first antigen-binding region comprises a variable heavy chain region comprising the sequence of SEQ ID NO. 29 and a variable light chain region comprising the sequence of SEQ ID NO. 33, said bispecific antibody further comprising a second antigen-binding region which binds to human CD3, wherein the second antigen-binding region comprises a variable heavy chain region comprising the sequence of SEQ ID NO. 17 and a variable light chain region comprising the sequence of SEQ ID NO. 22.
26. The bispecific antibody of claim 24 , wherein the antibody further comprises a first heavy chain constant region and a second heavy chain constant region and a first light chain constant region and a second light chain constant region, wherein said first heavy chain constant region comprises the sequence of SEQ ID NO. 61 and said second heavy chain constant region comprises the sequence of SEQ ID NO. 60, and wherein said first light chain constant region comprises the sequence of SEQ ID NO. 63 and said second light chain constant region comprises the sequence of SEQ ID NO. 64.
27. The bispecific antibody of claim 25 , wherein the antibody further comprises a first heavy chain constant region and a second heavy chain constant region and a first light chain constant region and a second light chain constant region, wherein said first heavy chain constant region comprises the sequence of SEQ ID NO. 61 and said second heavy chain constant region comprises the sequence of SEQ ID NO. 60, and wherein said first light chain constant region comprises the sequence of SEQ ID NO. 63 and said second light chain constant region comprises the sequence of SEQ ID NO. 64.
28. The bispecific antibody of claim 26 , wherein at least one of the heavy chain constant regions lacks the C-terminal lysine.
29. The bispecific antibody of claim 27 , wherein at least one of the heavy chain constant regions lacks the C-terminal lysine.
30. The bispecific antibody of claim 29 , wherein both heavy chain constant regions lack the C-terminal lysine.